Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

Inclusion Criteria: * Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. * Life expectancy of 12 weeks or greater. * ECOG Performance Status less than or equal to 2. * Meets protocol requirements for specified laboratory values. * No manifestations of a malabsorption syndrome. Exclusion Criteria: * Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease. * Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions. * Patients who have received investigational therapy of any type within 30 days prior to administration.